Abstract Body

Background

The effect of antiretroviral therapy (ART) initiation before conception and at different stages of gestation on adverse perinatal outcomes remains uncertain, as existing studies yield conflicting results. Few studies evaluate how the timing of dolutegravir (DTG)-based ART initiation during pregnancy affects perinatal outcomes.

Methods

We analyzed data from pregnant women living with HIV (WLHIV) enrolled in an ongoing cohort study at 8 public antenatal clinics in Western Kenya. WLHIV on DTG-ART were enrolled during pregnancy and followed through 36 months postpartum. ART initiation dates and perinatal outcomes were ascertained by study nurses from medical records. Log-binomial regression was used to evaluate the association between timing of maternal DTG initiation (pre-conception, 1st trimester, 2nd trimester and perinatal outcomes among WLHIV who remained pregnant beyond 20 weeks, including stillbirth (≥20 weeks’ gestation), preterm delivery (PTD) <37 weeks, and small-for-gestational age (SGA) <10th percentile. Models were adjusted for primigravidity, ART adherence, and maternal age, and multiple pregnancies were excluded.

Results

As of September 2025, 454 WLHIV enrolled in the study at a median gestational age of 21 weeks (IQR 14-27) and had pregnancy outcome data. Overall, 156 (34%) initiated DTG pre-conception and were on DTG for a median of 36 months (IQR 20-46). Among WLHIV who initiated DTG in pregnancy, 147 (33%) initiated during the 1st trimester at a median of 10 weeks (IQR 6-12), and 151 (33%) during the 2nd trimester at a median of 20 weeks (IQR 17-23). Most (99%) remained pregnant until at least 20 weeks gestation and among those (n=451) 5% experienced stillbirth, 10% PTD, and 17% SGA; 30% had any adverse pregnancy outcome. Compared with WLHIV who initiated DTG pre-conception, those who initiated DTG in the 1st-trimester had higher frequency of any adverse pregnancy outcome (39% vs. 25%, aRR=2.03, 95% CI 1.38–2.99, p<0.001) and SGA (23% vs. 14%, aRR=2.25, 95% CI 1.60, 3.16, p<0.001); there were no differences in stillbirth rates. Perinatal outcomes did not differ between WLHIV who initiated DTG in the 2nd trimester vs pre-conception (Table 1).

Conclusions

In this cohort of WLHIV in Kenya, 1st trimester DTG-initiation was associated with higher risk of adverse perinatal outcomes compared to pre-conception DTG-initiation. Our findings support current guidelines for HIV testing and ART initiation as early as possible, ideally prior to conception.

Table or Figure